Pharmadrug (PHRX) AI Stock Analysis

• Market Cap: C$1.62M
• Dividend Yield: N/A
• Average Volume (3M): 101.80K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.07
• Revenue Growth: N/A
• EPS Growth: 98.93%
• Country: CA
• Employees: 9
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): >-0.01
• Shares Outstanding: 108,234,380
• 10 Day Avg. Volume: 83,723
• 30 Day Avg. Volume: 101,798
• PEG Ratio: 0.01
• Price to Book (P/B): -0.74
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.35
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 39 Underperform
• Price Target: <C$0.01 ▼(-55.00% Downside)
• Action: Downgraded Date: 02/03/26
• Date: Action: Downgraded 02/03/26

The score is driven primarily by very weak financial performance (revenue collapse, ongoing losses, negative cash flow, and negative equity). Technicals also remain bearish with the stock trading below major moving averages and negative MACD. Valuation offers limited support due to negative earnings and no dividend yield.

Positive Factors

Regulatory and partnership focus

A strategic emphasis on regulatory pathways and evaluating assets/partnerships is a durable business-model lever. Successful regulatory progress or distribution partnerships can enable commercialization, de-risk R&D spend, and convert pipeline value into recurring revenue over the medium term.

Lower absolute debt vs prior peak

Debt having declined from its 2019 peak improves financial flexibility relative to that high-water mark. Lower absolute leverage reduces interest and covenant pressure, extending operational runway and giving management more options to pursue partnerships or reorganize without acute debt overhang.

Improved cash burn trend vs earlier years

A demonstrable improvement in cash burn versus the 2021–2022 period indicates better cost control or smaller cash needs. If sustained, this structural improvement lengthens runway, reduces reliance on frequent financing, and allows more deliberate strategic decisions over the next several quarters.

Negative Factors

Revenue collapse to near zero

Sustained near-zero revenue across multiple years is a profound structural weakness: without recurring sales, the company cannot generate internal funding for R&D or commercialization. This undermines long-term viability and forces dependence on external financing or asset disposals.

Negative shareholder equity (solvency risk)

Negative equity signals solvency strain and reduces creditor and investor confidence. It constrains access to conventional financing, may trigger covenants or creditor actions, and limits the company's ability to invest or pursue partnerships, posing a persistent structural constraint.

Consistent negative operating and free cash flow

Persistent negative operating and free cash flow means the business cannot self-fund operations or growth. Long-term reliance on external funding dilutes shareholders or increases leverage, reducing resilience to shocks and making sustained product development or commercialization harder.

Pharmadrug Business Overview & Revenue Model

Company Description

Pharmadrug Inc. operates as a specialty pharmaceutical company. It focuses on the research, development, and commercialization of controlled-substances and natural medicines, such as psychedelics, cannabis, and naturally-derived approved drugs. It also imports and distributes medical cannabis to pharmacies in Germany and rest of the European Union; and owns and operates Super Smart, an entity building to elevate the use of functional mushrooms and psilocybin mushrooms. In addition, the company engages in the researching and reformulating established natural medicines. It has a research agreement with the University of Michigan to evaluate N, N-dimethyltryptamine's (DMT) potential role in normal, diseased, and altered states of consciousness, as well as an agreement with Southwest Research Institute for initiating non-clinical and clinical manufacturing of cepharanthine; and clinical trial agreement with Johns Hopkins University to conduct a clinical study comparing acute and enduring psychological and neural effects of DMT and an undisclosed potently active comparator molecule. The company was formerly known as Aura Health Inc. and changed its name to Pharmadrug Inc. in October 2019. The company is based in Toronto, Canada.

How the Company Makes Money

Pharmadrug makes money primarily through the sale and licensing of its pharmaceutical products. The company's revenue streams include direct sales of its therapies to healthcare providers, partnerships with other pharmaceutical firms for the co-development and distribution of drugs, and licensing agreements that allow third parties to market and sell its products in different regions. Pharmadrug may also engage in research collaborations with academic institutions and other biotech companies, generating additional income through milestone payments and royalties. Furthermore, the company could potentially benefit from government grants or incentives for developing innovative treatments in under-served therapeutic areas.

Pharmadrug Financial Statement Overview

Summary

Financials indicate severe weakness: revenue has effectively collapsed to near zero (2022–2024), losses persist, operating and free cash flow are consistently negative, and shareholder equity is negative in 2023–2024 (solvency red flag).

Income Statement

Operating performance is very weak. Revenue has effectively collapsed to zero in the last three annual periods (2022–2024), and profitability remains deeply negative with sizable operating losses and net losses each year (2024 net loss of ~0.8M following a much larger ~13.2M loss in 2023). Earlier years (2019–2021) showed meaningful revenue, but margins were still strongly negative, highlighting a persistent inability to generate sustainable earnings.

Balance Sheet

The balance sheet is stressed, with negative shareholder equity in 2023 and 2024 (a clear solvency red flag) alongside meaningful debt (~1.35M in 2024). Total assets have also declined materially versus 2020–2022 levels, reducing financial flexibility. A positive is that total debt is lower than the 2019 peak, but the shift into negative equity outweighs that improvement and increases balance-sheet risk.

Cash Flow

Cash generation is weak and consistently negative: operating cash flow and free cash flow were negative across all years provided, including ~(-0.76M) operating cash flow and ~(-0.77M) free cash flow in 2024. The pace of cash burn improved versus earlier years (notably 2021–2022), but free cash flow growth turned sharply negative in 2024, signaling renewed pressure. Overall, the business appears reliant on external funding to sustain operations.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	7.01K	683.67K
Gross Profit	-50.24K	-50.24K	-26.22K	-2.26K	-2.15K	182.04K
EBITDA	-133.04K	-549.04K	-1.33M	-2.34M	-4.21M	-4.28M
Net Income	-337.94K	-793.27K	-13.20M	-8.88M	-5.87M	-5.15M
Balance Sheet
Total Assets	578.37K	711.80K	1.20M	12.11M	19.52M	13.69M
Cash, Cash Equivalents and Short-Term Investments	17.72K	75.04K	423.06K	329.24K	1.30M	4.40M
Total Debt	1.43M	1.35M	1.77M	1.42M	866.37K	1.13M
Total Liabilities	2.00M	1.96M	2.66M	3.28M	2.66M	3.12M
Stockholders Equity	-1.55M	-1.40M	-1.70M	8.84M	16.87M	9.66M
Cash Flow
Free Cash Flow	-80.92K	-768.60K	-671.88K	-2.26M	-4.17M	-1.43M
Operating Cash Flow	-80.92K	-756.62K	-671.88K	-2.26M	-4.13M	-1.41M
Investing Cash Flow	-11.98K	-11.98K	995.04K	77.58K	1.48M	3.78M
Financing Cash Flow	-4.44K	321.56K	225.51K	843.25K	776.97K	132.24K

Pharmadrug Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.02
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:PHRX, the sentiment is Positive. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.02, and above the 200-day MA of 0.01, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 57.39 is Neutral, neither overbought nor oversold. The STOCH value of 200.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:PHRX.

Pharmadrug Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
INNO	46 Neutral	C$30.37M	-6.75	-71.80%	―	-3.94%	-17.62%
RAMM	45 Neutral	C$2.39M	-0.18	-69.77%	―	-15.51%	-49.26%
RVV	44 Neutral	C$6.28M	-0.59	-664.21%	―	―	-80.42%
MVMD	42 Neutral	C$5.29M	-0.71	-148.48%	―	-46.59%	8.26%
PHRX	39 Underperform	C$1.62M	-6.52	―	―	―	98.93%
AION	31 Underperform	C$2.42M	-0.64	―	―	563.34%	-68.82%

Pharmadrug Corporate Events

PharmaDrug Takes 19.9% Stake in Canurta and Restructures Capital to Advance Botanical Drug Portfolio

PharmaDrug has closed the first tranche of its acquisition of a 19.9% interest in Canurta Inc.’s parent entity, Canurta Limited Partnership, through the issuance of 25,980,000 common shares, and has added Canurta founder and CEO Akeem Gardner to its board of directors. The deal, which includes a forgivable working-capital loan from Canurta and is structured to increase PharmaDrug’s stake to 40% by a second tranche expected by March 31, 2026, positions PharmaDrug to advance its cepharanthine development and Phase 1 clinical trial in Australia while significantly integrating Canurta’s botanical IP portfolio and shareholders into its capital structure, potentially reshaping ownership and strengthening its standing in the natural-medicines biotech space.

The most recent analyst rating on (TSE:PHRX) stock is a Hold with a C$0.02 price target. To see the full list of analyst forecasts on Pharmadrug stock, see the TSE:PHRX Stock Forecast page.